Superior In Vivo Efficacy of Fermented Over Aqueous Astragalus membranaceus in Diabetic Nephropathy: A Systematic Pharmacological Evaluation and Mechanistic Study.

Diabetic nephropathy (DN) is a major microvascular complication of diabetes and a leading cause of end-stage renal disease, with current treatments failing to halt progression, creating demand for better interventions. Astragalus membranaceus shows promise for DN, and microbial fermentation enhances herbal bioavailability and efficacy. This study compared fermented A. membranaceus broth (FA) and its aqueous extract (EA) in streptozotocin-induced DN rats, with 8-week low/medium/high-dose treatment. FA outperformed EA in improving metabolic parameters and renal function: superior body weight recovery, greater reductions in fasting blood glucose, serum BUN, ALT, and TG, enhanced renal antioxidant capacity (elevated SOD/GSH-Px and reduced MDA), and alleviated glomerular/tubular injury and interstitial inflammation. Chemical profiling identified 14 FA bioactive components; network pharmacology revealed core targets (STAT3, IL6, and TGFB1) and key pathways (AGE-RAGE, HIF-1, and FoxO). Fermentation boosts A. membranaceus efficacy in DN via better active constituent bioavailability, conferring stronger antioxidant, metabolic, and renoprotective effects, making FA a promising therapeutic and bioprocessing a strategy to upgrade traditional herbs.